This week: the side-effect piece we promised, because “it gets worse before it gets better” should never mean guessing which kind of worse, and a gray-market compound that finally gets its grade.

Let's go. ☕

Annoying or an emergency? Your GLP-1 side effects, sorted.

That sentence, or something very close to it, shows up constantly in GLP-1 communities. And it is exactly why this piece exists. Most side effects really are the annoying kind. Some are not. The harder part is knowing when “normal adjustment” stops being a useful explanation. Here's the plain-English version.

The annoying kind, and why it clusters where it does

Nausea. Diarrhea. Vomiting. Constipation. Abdominal discomfort. Those are the big GI side effects across the semaglutide and tirzepatide labels. With the weight-management products, you also see things like indigestion, reflux, burping and fatigue.

And yes, timing matters. GI symptoms often cluster around dose escalation. Wegovy trials reported more GI reactions during dose increases, and with Zepbound, most nausea, vomiting and diarrhea occurred during escalation and decreased over time. That is the true part of “give your body time to adjust.” Many people do. But “common” is not the same as “ignore it.” The phrase stops being useful when symptoms are severe, persistent or clearly getting worse.

The red flags, straight from the labels

This is the part worth saving. Not every symptom below means “go to the ER right now.” Some mean contact your prescriber promptly. Some do need urgent evaluation. The point is that these should not automatically be written off as normal adjustment.

• Severe or persistent abdominal pain, especially if it spreads to your back, with or without nausea or vomiting: that is the label language around possible pancreatitis.
• Upper abdominal pain, fever, yellowing of the skin or eyes, or clay-colored stools: possible gallbladder trouble. Gallbladder disease is a known risk, and substantial or rapid weight loss can add to gallstone risk.
• Persistent vomiting or diarrhea, especially when you are struggling to keep up with fluids: this is where dehydration itself starts to matter. Both labels warn that fluid loss from GI symptoms can contribute to acute kidney injury. There is no official “24-hour rule.” Severity, persistence and whether you can stay hydrated matter more than the clock.
• Severe constipation that is not improving, especially with significant abdominal pain, swelling or vomiting: do not assume it is ordinary constipation. Ileus, intestinal obstruction and severe constipation, including fecal impaction, have been reported after marketing with semaglutide and tirzepatide. That does not mean every bad constipation episode is an obstruction. It means severe symptoms deserve evaluation.
• Changes in vision if you have type 2 diabetes, especially if you already have diabetic retinopathy: both semaglutide and tirzepatide now carry diabetic-retinopathy warnings.
• Swelling of the face, lips, tongue or throat, or trouble breathing or swallowing: that is serious allergic-reaction territory and needs immediate medical attention.
• A lump or swelling in the neck, persistent hoarseness, trouble swallowing or trouble breathing: those are symptoms the labels tell patients to report in connection with the thyroid C-cell tumor warning. One important piece of context: that boxed warning comes from thyroid C-cell tumors seen in rodents. Whether semaglutide or tirzepatide causes medullary thyroid cancer in humans is still unknown.

So no, every symptom is not an emergency. But every symptom is also not “just the medication working.”

The pattern that should change your math

There is a difference between “I felt nauseated after my dose went up and now I'm feeling better” and “I keep vomiting, I'm barely drinking, and this is getting worse.” The trials support the first pattern as something that commonly happens around dose escalation. The labels are very clear that the second pattern deserves attention. That is where the toughness contest needs to end.

And if you are sitting in an online group asking strangers whether something might be an emergency, that is usually a sign that the group has reached the limit of what it can do for you. Communities are great at “me too.” They are not great at “is this pancreatitis, dehydration or nothing serious?” That question belongs with someone who can actually assess you.

The woman-specific layer

There are three things here worth pulling out. First, gallstones are already more common in women, and rapid weight loss is another known risk factor. That does not mean every woman on a GLP-1 will develop gallbladder disease. It does mean gallbladder symptoms are worth recognizing rather than automatically blaming on “GLP-1 stomach.”

Second, menstrual changes are still not formally characterized as adverse reactions in the semaglutide or tirzepatide labels. But there is an emerging signal. A 2026 analysis of FDA adverse-event reports found disproportionate reporting of several menstrual changes with semaglutide, including heavy menstrual bleeding, intermenstrual bleeding, menstrual clots, oligomenorrhea and anovulatory cycles. Tirzepatide showed more limited signals for intermenstrual bleeding and menstrual clots. That type of study cannot prove the drug caused the events. It does tell us the question deserves better research. So if your cycle changes, track it and bring it up.

Third, the tirzepatide contraception warning is very real and very practical. Zepbound advises people using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting treatment and for four weeks after each dose increase. That one is not a social-media theory. It is in the prescribing information.

What to do with this

• Keep a simple note when symptoms show up: what happened, when it started, whether it followed a dose change and whether it is improving.
• Learn the red flags above, but remember that “red flag” does not mean every symptom has the same level of urgency.
• If vomiting or diarrhea is persistent or you are struggling to keep fluids down, contact your healthcare provider promptly. Do not wait for an arbitrary 24-hour cutoff.
• If you have severe abdominal pain, trouble breathing, significant facial or throat swelling, fainting or other severe symptoms, get urgent medical help.
• Report suspected adverse reactions through FDA MedWatch. With compounded and gray-market products under so much scrutiny, those reports matter.

And that is interesting because emerging real-world evidence suggests women may experience GI symptoms more often. In a recent cohort of more than 78,000 GLP-1 users, women had about a 40% higher risk of GI symptom events than men. That does not mean women need a different dose; we do not have evidence establishing that. It means the people using these medications are disproportionately women, while we still have a lot to learn about whether sex and life stage change the experience of treatment. That gap is worth paying attention to.

“Gray-market retatrutide is the same drug as the one in the trials, just cheaper.”

What the evidence says. Retatrutide is a real investigational drug. It is a single molecule that activates GIP, GLP-1 and glucagon receptors, and Lilly is studying it in Phase 3 clinical trials. It is not FDA-approved and is not available for public use. So anything you can currently buy online as “Reta” is not an FDA-approved retail version of Lilly's trial drug.

And this month, CBS bought three products sold as retatrutide and sent them to University of Iowa researchers for testing. The results were actually more complicated than “all the vials were fake.” Two products purchased online were consistent with a basic laboratory standard the researcher created for retatrutide. But that does not establish that they were equivalent to Lilly's clinical-trial product, correctly dosed, sterile or manufactured to pharmaceutical standards. The third vial, bought at a Brooklyn bodega, was a different story. Researchers did not detect a peptide. Instead, they found phenylacetic acid. Microbiology testing also found 13 bacterial colonies in the sample.

That is the gray market in one experiment. Sometimes testing may find something consistent with the molecule named on the vial. Sometimes it may not. And you usually do not have the pharmaceutical-quality system needed to know the difference.

Australia has already provided the uglier version of that lesson. Clinicians in Victoria reported seven cases of acute liver toxicity in people who had used black-market products labeled retatrutide. Doctors suspected a possible contaminated batch, but testing had not established contamination as the cause. Separate Australian testing also found major dose and identity problems in products carrying the retatrutide name. In one investigation, two of three tested vials contained substantially more retatrutide than the label claimed. And in another case, a product labeled as retatrutide contained no retatrutide at all. Testing instead found a high amount of undeclared semaglutide.

That distinction matters. Serious harms have been reported after use of these products. That does not prove retatrutide itself caused every injury. Because with a gray-market vial, you may not actually know what caused anything.

Trial participants get a verified investigational product, a known protocol, clinical monitoring and an adverse-event reporting system. A vial from a website does not come with that infrastructure. And a seller-posted certificate of analysis does not magically create it. A COA tells you what was tested in a particular sample using particular methods. It does not guarantee that the vial in your hand has the same identity, concentration, sterility, endotoxin status or contamination profile. Australian investigators have raised this exact limitation when discussing peptide testing. That is not a small difference. That is most of the difference.

The fair version of the claim: retatrutide is genuinely interesting. That is exactly why it is being studied. If it eventually earns FDA approval, it will come with a verified manufacturing process, quality controls, prescribing information and a defined safety system. Until then, curiosity is free. The vial is the gamble.

Worth your inbox

Researching health for yourself is one job. Doing it for an aging parent at the same time is two. GrayBrief is a plain-English education resource for adult children navigating elder care: what to ask, what to watch for, and what nobody tells you until it's urgent. If that's your season of life, it's worth a look.

Three days of vomiting and barely being able to keep fluids down is not something I would keep waiting out. I would contact your prescriber or get same-day medical evaluation.

Nausea and vomiting can happen after a dose increase, and for many people they improve with time. But persistent vomiting is different because dehydration becomes a risk of its own. Both the semaglutide and tirzepatide prescribing information warn that ongoing nausea, vomiting or diarrhea can cause enough fluid loss to contribute to acute kidney injury.

I would not use a strict “24-hour rule.” The labels do not give one. How severe the symptoms are and whether you can stay hydrated matter more than the number of hours. If you also have severe or persistent abdominal pain, are urinating much less than usual, feel faint or significantly lightheaded, have trouble breathing, or develop swelling of your face or throat, the urgency goes up. That is not a group-chat question.

Your group is right about one thing: adjustment symptoms are common. But common does not mean every symptom should be pushed through. If you are barely keeping water down, it is time to get an actual clinician involved.

Mais, PharmD, Medical Reviewer, Pep in Her Step

• Copper peptides, from serum to syringe: why the jump is bigger than your feed says.
• GLP-1s and drinking less: the off-label effect women keep reporting, and what the research actually supports.
• Pill versus pen: what the oral semaglutide data actually shows.